Lv444
600 积分 2025-11-10 加入
Recent update on the development of EZH2 inhibitors and degraders for cancer therapy
10小时前
待确认
Therapeutic Horizons in Targeting EZH2 With Dual and Non-PROTAC Inhibitor Molecules: Recent Achievements, Comparative Analysis, and Future Perspectives
10小时前
待确认
Discovery of Histone Deacetylase 8-Specific Proteolysis-Targeting Chimeras with Anticancer Activity against Hematological Malignancies
1天前
待确认
81 (PB069): A novel BRD4 degrader, MT-4561, exerts continuous anti-tumor effects in various cancer xenograft model and patient derived cells
1天前
待确认
HSP90 Mediates Targeted Degradation of Nonclient Protein PARP1 for Breast Cancer Treatment
2天前
已完结
Molecular chaperones: functional mechanisms and nanotechnological applications
2天前
已关闭
Abstract 4503: Preclinical characterization of PRT7732: A highly potent, selective, and orally bioavailable targeted protein degrader of SMARCA2
2天前
已关闭
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4 -Mutated Cancers
3天前
已完结
皖公网安备34019202002308
